Tesamorelin vs growth hormone: what the evidence shows

Last updated 2026-07-24

What is the actual difference between tesamorelin and growth hormone?

Tesamorelin is not growth hormone. It's a growth hormone-releasing hormone (GHRH) analogue, a 44-amino acid peptide that binds receptors on your pituitary gland and tells it to make and release your own growth hormone in a pulsatile pattern ^[1]. Human growth hormone (HGH, generic name somatropin) is the actual hormone, made recombinantly and injected directly, bypassing the pituitary entirely. That distinction matters more than it sounds. Tesamorelin works only if your pituitary still has functioning somatotroph cells, and it preserves the body's normal feedback loops (somatostatin can still put the brakes on) ^[2]. Direct HGH injection overrides that loop and delivers a fixed dose regardless of what your body would naturally produce. Both ultimately raise IGF-1 and circulating GH. But the delivery mechanism is different enough that regulators, researchers, and insurers treat them as separate categories, with separate approval pathways and separate evidence bases. Tesamorelin is FDA-approved under the brand name Egrifta (and its follow-on SV formulation) specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[1][3]. Somatropin products are approved for pediatric growth failure, adult GH deficiency, and a handful of other specific diagnoses, not for general fat loss or anti-aging use in healthy adults.

Is tesamorelin FDA-approved and what exactly is it approved for?

Yes. Tesamorelin (Egrifta) carries FDA approval, but the indication is narrow: reduction of excess visceral abdominal fat in HIV-positive patients with lipodystrophy ^[1][4]. It is not approved for weight loss in people without HIV, not approved for bodybuilding or athletic performance, and not approved as an anti-aging therapy. The approval rests on two pooled multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data, published in the Journal of Clinical Endocrinology and Metabolism in 2010 ^[4]. That's a real evidentiary bar most peptides marketed online never clear. A 2011 review in Drugs summarized the same lipodystrophy indication and use pattern ^[5], and a companion pharmacotherapy review in 2012 covered dosing and adverse event profile in that population ^[6]. Any use of tesamorelin outside HIV-associated lipodystrophy, for general visceral fat reduction, muscle gain, sleep, or recovery, is off-label. Off-label prescribing is legal and common in medicine, but it means the specific outcome you're chasing hasn't been tested in the same rigorous trial the FDA approval is based on. See our full tesamorelin overview for the mechanism and indication in more depth.

How does tesamorelin's trial evidence compare to growth hormone's?

Tesamorelin's core evidence is a matched pair of phase 3 randomized controlled trials pooled for FDA review, showing measurable visceral adipose tissue (VAT) reduction and safety extension data over roughly a year of dosing ^[4]. That's a tighter, more indication-specific dataset than exists for most off-label HGH protocols aimed at fat loss in the general population. A 2026 meta-analysis of randomized controlled trials pooled tesamorelin's effects on body composition, hepatic fat, and metabolic and safety outcomes specifically in HIV-associated lipodystrophy ^[7]. That confirms the strongest data sits inside that one population. A 2021 study found tesamorelin improves visceral fat quality independent of changes in fat quantity, meaning it can reduce lipoattenuation (a marker of unhealthy fat) even in patients whose total fat mass doesn't shift dramatically ^[8]. Growth hormone itself, prescribed on-label for confirmed adult GH deficiency or pediatric growth failure, also has decades of trial data, but that data describes replacement therapy in deficient patients, not fat loss in metabolically normal or HIV-positive adults with intact GH axes. A 2013 review on growth hormone in aging men found the evidence for GH therapy improving body composition in older men is mixed and comes with real safety tradeoffs including fluid retention and glucose effects ^[9]. Nobody has run a tesamorelin-equivalent phase 3 program testing raw HGH for visceral fat in HIV patients; the comparison arm simply doesn't exist in that population. What's better studied than either drug in isolation is what happens when you stop. Tesamorelin's trials show VAT tends to creep back after discontinuation, which is why ongoing therapy, not a fixed course, is the approved model ^[4][10].

How do tesamorelin and HGH compare on visceral fat and liver fat?

Tesamorelin has the more specific liver data. A 2019 randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat and was associated with improvements in non-alcoholic fatty liver disease markers in people with HIV, versus placebo ^[10]. A related 2017 study linked visceral fat reduction from tesamorelin to improved liver enzymes in the same population ^[11], and mechanistic follow-up work using transcriptomic and proteomic profiling has tried to map exactly which liver pathways tesamorelin affects ^[12][13]. That liver angle is a genuine point of separation. Direct HGH replacement in deficient adults improves body composition broadly, but it isn't studied as a targeted hepatic fat therapy in HIV populations the way tesamorelin is. | Feature | Tesamorelin (Egrifta) | Recombinant HGH (somatropin) |

Does tesamorelin work as well as HGH for reducing visceral fat?

Within its studied population (HIV-associated lipodystrophy), tesamorelin has clear, replicated evidence of VAT reduction from randomized, placebo-controlled trials ^[4]. Outside that population, honest answer: nobody has run a comparably rigorous head-to-head trial against HGH for visceral fat in the general public, so any claim of one being 'better' for that use is not something the literature actually supports. A 2024 study looked at efficacy and safety of tesamorelin specifically in people with HIV on modern integrase inhibitor regimens, finding the drug's effect held up in this contemporary treatment context ^[14]. That's a meaningfully updated data point, since HIV antiretroviral regimens have changed a lot since the original phase 3 trials. A 2023 post hoc analysis of the phase 3 placebo-controlled trial data looked specifically at patients with and without dorsocervical fat pads ('buffalo hump'), finding treatment effects varied by that baseline characteristic ^[15]. That level of subgroup granularity is exactly what you'd expect from a mature, FDA-reviewed dataset, and it's not something available for general-population HGH-for-fat-loss protocols.

Which has a better safety profile, tesamorelin or growth hormone?

Tesamorelin's most common adverse events in trials were injection site reactions, joint pain (arthralgia), and swelling, tracked across the phase 3 program and its safety extension ^[4][6]. Because it stimulates rather than replaces GH, it carries a theoretically lower risk of overshooting GH levels compared to fixed-dose exogenous HGH, though direct comparative safety trials between the two don't exist. A 2011 study specifically examined inflammatory markers in HIV patients on tesamorelin and their relationship to visceral fat reduction, adding some mechanistic detail to the drug's downstream metabolic effects ^[16]. Growth hormone replacement, when used on-label for confirmed deficiency, has its own well-documented risk profile: fluid retention, joint pain, carpal tunnel symptoms, and effects on glucose metabolism, especially in older adults, as reviewed in the 2013 aging-male literature ^[9]. Neither drug is risk-free. And neither should be self-administered without lab work and physician oversight. If you're weighing side effects specifically for tesamorelin, the fuller list (and what's actually common versus rare) is in our tesamorelin peptide side effects breakdown.

Are tesamorelin and HGH dosed the same way?

No, and this is one of the more practical differences. Tesamorelin is dosed as a daily subcutaneous injection, typically 1-2 mg depending on formulation and reconstitution, based on the population pharmacokinetic modeling published in 2015 covering both HIV-infected patients and healthy subjects ^[17]. HGH dosing for approved deficiency indications is calculated differently, often by body weight or IGF-1 titration, and follows separate protocols entirely. Because tesamorelin's approved dosing was worked out in controlled trials with defined populations, there's a real pharmacokinetic map to work from. That's a genuine advantage for anyone actually trying to dose correctly rather than guessing. Our tesamorelin dosage guide and tesamorelin dosage calculator walk through the specifics, and the tesamorelin reconstitution page covers mixing the lyophilized powder correctly, since a botched reconstitution is one of the more common real-world errors with this drug.

Can tesamorelin cause the same side effects as growth hormone injections?

There's overlap. Both can cause joint pain, fluid retention, and injection site reactions because both ultimately raise circulating GH and IGF-1 ^[4][9]. Tesamorelin's trials also flagged possible glucose intolerance as a monitoring point, which is why blood sugar tracking is standard practice during treatment, similar to what's watched with direct HGH therapy. Where they likely differ is degree. Because tesamorelin stimulates a regulated, pulsatile release rather than delivering a flat exogenous dose, some clinicians consider it less likely to produce the more dramatic supraphysiologic IGF-1 spikes seen with poorly dosed HGH. That's a plausible mechanistic argument, not a proven comparative safety finding, since the head-to-head trial that would prove it hasn't been run.

Is tesamorelin legal and is it the same as buying growth hormone peptides online?

Tesamorelin as Egrifta is a legitimately FDA-approved prescription drug, obtained through a pharmacy with a valid prescription. That's a different legal and quality category from generic 'GH peptides' sold research-only online with no prescription, no FDA review, and no chain of custody guarantee. Compounded tesamorelin also exists, prepared by 503A or 503B pharmacies under federal compounding law. Bulk tesamorelin's regulatory status for compounding is governed by 21 CFR 216.23 for 503A facilities and 21 CFR 216.24 for 503B outsourcing facilities ^[18][19], with the underlying compounding authority coming from 21 U.S.C. 353a ^[20]. The FDA maintains a running list of bulk drug substances nominated for compounding use ^[21], and its own guidance page on bulk substances under section 503A lays out how that evaluation works ^[22]. Intended use also matters under the law. FDA's regulation on the meaning of 'intended uses,' 21 CFR 201.128, is part of why marketing a compounded or research peptide for a use the approved drug was never studied for creates real regulatory exposure for sellers ^[23]. If you're sourcing tesamorelin, insist on a provider-reviewed pathway with a named, licensed pharmacy behind it rather than an unlabeled vial from an unverified seller. Tesamorelin Co works from that provider-reviewed model, connecting the evidence in this article to a fulfilling pharmacy partner rather than compounding or manufacturing anything itself.

What does tesamorelin cost compared to growth hormone therapy?

Branded Egrifta and Egrifta SV list prices run into the thousands of dollars per month without insurance coverage, reflecting its status as a specialty biologic-adjacent peptide with a narrow FDA-approved population. Compounded tesamorelin, where legally available through a 503A or 503B pharmacy, is typically cheaper but doesn't carry the same FDA product-specific review as the branded version. Recombinant HGH for approved deficiency indications is also expensive, often comparable to or higher than branded tesamorelin, and is usually covered by insurance only when deficiency is confirmed through appropriate stimulation testing. Neither drug is cheap. Anyone quoting a bargain price for either one, especially unlabeled online, deserves scrutiny. Full current pricing detail, including what drives the cost difference between compounded and branded product, is in our tesamorelin cost guide.

Who is actually a candidate for tesamorelin versus growth hormone therapy?

The clearest candidate for tesamorelin, by the approved label, is an adult with HIV and confirmed lipodystrophy with excess abdominal visceral fat, under the care of a physician who can monitor IGF-1, glucose, and injection site tolerance ^[1][4]. That's a specific, diagnosable clinical picture, not a general 'I want less belly fat' profile. The clearest candidate for HGH replacement is an adult or child with confirmed GH deficiency, diagnosed through appropriate stimulation testing and clinical criteria, not simply low-normal IGF-1 on a single blood draw. A 2022 review on the approach to patients with lipodystrophy highlights how much diagnostic workup (imaging, metabolic labs, sometimes genetic testing) properly precedes any GHRH-analogue or GH therapy decision ^[24], and a 2012 paper specifically on diagnosing lipodystrophy syndromes lays out the criteria clinicians use ^[25]. People chasing general anti-aging effects, athletic recovery, or fat loss without HIV-associated lipodystrophy or confirmed GH deficiency are, by definition, using either drug off-label, and the trial evidence supporting that use is far thinner than what's cited above for the approved indications.

Where does tesamorelin fit against other peptides used for similar goals?

Tesamorelin sits in a broader category of therapeutic peptides increasingly used in orthopaedic, sports medicine, and metabolic contexts, though most of that broader use remains far less studied than tesamorelin's HIV lipodystrophy indication. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics generally, flagging both promise and real evidence gaps across the category ^[26]. A companion 2026 primer in the American Journal of Sports Medicine walked sports medicine physicians through injectable peptide therapy considerations more broadly ^[27], and a 2026 Sports Medicine review specifically assessed safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance, a useful reminder that 'peptide' does not mean 'equally studied' across the category ^[28]. A separate 2026 review in the International Journal of Molecular Sciences looked at therapeutic peptides across aesthetic, metabolic, and endocrine conditions, again showing that evidence quality varies enormously peptide to peptide ^[29]. Tesamorelin's phase 3 program puts it well ahead of most peptides in that broader field on evidence quality, even though its approved use case is narrow. Worth noting separately: anti-doping labs have developed specific methods to detect synthetic GHRH analogues like tesamorelin in athletes, according to a 2021 review in Drug Testing and Analysis ^[30], which tells you regulators already treat GHRH analogues as a distinct, monitorable drug class rather than a loophole around GH bans.

Frequently asked questions

Is tesamorelin the same thing as HGH?

No. Tesamorelin is a GHRH analogue that stimulates your pituitary to release your own growth hormone. HGH (somatropin) is the hormone itself, given by direct injection. Tesamorelin preserves your body's natural feedback loop; injected HGH bypasses it entirely with a fixed exogenous dose.

Is tesamorelin FDA-approved for weight loss?

No. Tesamorelin (Egrifta) is FDA-approved only for reducing excess abdominal visceral fat in HIV-associated lipodystrophy, based on pooled phase 3 trial data. It is not approved for general weight loss, bodybuilding, or anti-aging use in people without that specific diagnosis.

Does tesamorelin raise growth hormone levels the same way HGH does?

It raises GH and IGF-1, but through a different route. Tesamorelin stimulates pulsatile release from the pituitary, subject to the body's own regulatory brakes like somatostatin. Direct HGH injection delivers a fixed dose regardless of the body's feedback signals, which is why dosing precision matters more with exogenous HGH.

Which is safer, tesamorelin or growth hormone injections?

No trial has directly compared their safety head-to-head. Tesamorelin's phase 3 program showed mostly injection site reactions, joint pain, and glucose monitoring flags. HGH replacement carries known risks of fluid retention and joint pain too. Because tesamorelin preserves natural feedback regulation, some clinicians consider it theoretically less prone to overshoot, but this isn't proven comparatively.

Can I get tesamorelin prescribed if I don't have HIV?

Only off-label. The FDA approval covers HIV-associated lipodystrophy specifically. Physicians can legally prescribe off-label for other purposes, but the strong phase 3 evidence backing tesamorelin's approval does not extend to those other uses, so expectations should be set accordingly.

How is tesamorelin dosed compared to growth hormone?

Tesamorelin is typically a daily subcutaneous injection, with dosing informed by population pharmacokinetic modeling in HIV patients and healthy subjects. HGH dosing for approved deficiency indications is usually calculated by body weight or titrated to IGF-1 levels, following a different protocol entirely.

Does tesamorelin help with liver fat like it does with visceral fat?

Yes, in its studied population. A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat and improved NAFLD-related markers in people with HIV, and a separate study linked its visceral fat reduction to improved liver enzymes in the same group.

Is compounded tesamorelin legal?

Compounded tesamorelin can be legally prepared by 503A or 503B pharmacies under federal compounding law, governed by specific bulk drug substance rules in 21 CFR 216.23 and 216.24. It is a different regulatory category from branded, FDA-approved Egrifta, and quality can vary by pharmacy.

What happens if you stop taking tesamorelin?

Trial data shows visceral fat tends to return after discontinuation, which is consistent with tesamorelin working as an ongoing stimulant of GH release rather than a one-time fix. This is why the approved use model is continued therapy, not a short fixed course.

Does tesamorelin build muscle like growth hormone is claimed to?

Tesamorelin's approved evidence is specifically about visceral fat reduction in HIV lipodystrophy, not muscle building. Any muscle-related claims for tesamorelin are extrapolated from GH's general effects on body composition and are not what its phase 3 trials were designed or powered to measure.

Can tesamorelin be detected in doping tests like HGH?

Yes. Anti-doping laboratories have developed specific detection methods for synthetic GHRH analogues, including tesamorelin, distinct from standard HGH tests, according to a 2021 review in Drug Testing and Analysis. Regulators treat GHRH analogues as their own monitorable drug class.

Which costs more, tesamorelin or HGH therapy?

Both are expensive. Branded Egrifta and Egrifta SV run into the thousands of dollars monthly without insurance. Recombinant HGH for confirmed deficiency is often comparably priced or higher. Compounded tesamorelin can cost less but lacks the branded product's FDA-specific review.

Sources

1. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin is a GHRH analogue and its FDA approval covers HIV-associated lipodystrophy
2. PubMed, Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009): Tesamorelin stimulates pituitary GH release while preserving normal feedback regulation
3. PubMed, Tesamorelin (2012): Tesamorelin overview covering its indication and drug class
4. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 trial analysis (JCEM, 2010): Pooled phase 3 double-blind placebo-controlled trials with safety extension data underpin the FDA approval and adverse event profile
5. PubMed, Tesamorelin: a review of its use in HIV-associated lipodystrophy (Drugs, 2011): Review summarizing tesamorelin's approved use pattern in HIV-associated lipodystrophy
6. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (Annals of Pharmacotherapy, 2012): Dosing and adverse event profile details for tesamorelin in HIV-associated lipodystrophy
7. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin: meta-analysis of RCTs (Obesity Research & Clinical Practice, 2026): Meta-analysis pooling tesamorelin RCT data on body composition, hepatic fat, and safety in HIV-associated lipodystrophy
8. PubMed, Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021): Tesamorelin can improve visceral fat quality (lipoattenuation) even without large changes in total fat quantity
9. PubMed, Growth hormone in the aging male (Best Practice & Research Clinical Endocrinology & Metabolism, 2013): Evidence for GH therapy improving body composition in aging men is mixed and carries safety tradeoffs like fluid retention and glucose effects
10. PubMed, Effects of tesamorelin on NAFLD in HIV: randomised double-blind trial (The Lancet HIV, 2019): Randomized double-blind multicenter trial found tesamorelin reduced hepatic fat and improved NAFLD markers versus placebo
11. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017): Visceral fat reduction from tesamorelin was linked to improved liver enzymes in HIV patients
12. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD (JCI Insight, 2020): Transcriptomic study mapping tesamorelin's effects on liver gene expression pathways in HIV-associated NAFLD
13. PubMed, Delineating tesamorelin response pathways using proteomic and transcriptomic approach (Scientific Reports, 2021): Proteomic and transcriptomic profiling used to identify tesamorelin's liver response pathways in HIV-associated NAFLD
14. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024): Tesamorelin's effect held up in people with HIV on contemporary integrase inhibitor antiretroviral regimens
15. PubMed, Effect of tesamorelin with and without dorsocervical fat: post hoc phase 3 analysis (Journal of Clinical and Translational Science, 2023): Post hoc analysis of phase 3 trial data found tesamorelin treatment effects varied by baseline dorsocervical fat pad status
16. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat (AIDS, 2011): Study examined inflammatory markers and their relationship to visceral fat reduction in tesamorelin-treated HIV patients
17. PubMed, Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects (Clinical Pharmacokinetics, 2015): Population pharmacokinetic modeling informs tesamorelin dosing in HIV-infected patients and healthy subjects
18. eCFR, 21 CFR 216.23, 503A Bulks List: Federal regulation governing bulk drug substances eligible for 503A pharmacy compounding
19. eCFR, 21 CFR 216.24, 503B Bulks List: Federal regulation governing bulk drug substances eligible for 503B outsourcing facility compounding
20. Cornell Law, 21 U.S.C. 353a, pharmacy compounding: Statutory authority underlying pharmacy compounding of drugs including tesamorelin
21. FDA, bulk drug substances nominated for use in compounding (current list): FDA maintains a running list of bulk drug substances nominated for compounding use
22. FDA, bulk drug substances used in compounding under section 503A: FDA guidance describing how bulk drug substances are evaluated for 503A compounding use
23. eCFR, 21 CFR 201.128, meaning of intended uses: Federal regulation defining intended use, relevant to marketing compounded or research peptides for unapproved purposes
24. PubMed, Approach to the Patient With Lipodystrophy (Journal of Clinical Endocrinology and Metabolism, 2022): Diagnostic workup including imaging, metabolic labs, and sometimes genetic testing should precede lipodystrophy treatment decisions
25. PubMed, How to diagnose a lipodystrophy syndrome (Annales d'Endocrinologie, 2012): Clinical criteria used by physicians to diagnose lipodystrophy syndromes
26. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026): Review of therapeutic peptides in orthopaedics identifying both promise and evidence gaps across the category
27. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (American Journal of Sports Medicine, 2026): Primer for sports medicine physicians on injectable peptide therapy considerations
28. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): Review assessing safety and efficacy differences between approved and unapproved peptide therapies for athletic performance
29. PubMed, Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions (International Journal of Molecular Sciences, 2026): Review of therapeutic peptides across aesthetic, metabolic, and endocrine conditions noting variable evidence quality
30. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Testing and Analysis, 2021): Anti-doping laboratories have developed specific detection methods for synthetic GHRH analogues like tesamorelin